GRCL Gracell Biotechnologies Inc. Stock Quote

GRCL [NASD]

Index	-	P/E	-	EPS (ttm)	-0.97	Insider Own	7.71%	Shs Outstand	67.30M	Perf Week	-10.51%
Market Cap	207.81M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	8.65M	Perf Month	36.36%
Income	-63.10M	PEG	-	EPS next Q	-0.08	Inst Own	47.00%	Short Float	6.69%	Perf Quarter	-1.25%
Sales	0.37M	P/S	567.77	EPS this Y	-36.70%	Inst Trans	-4.09%	Short Ratio	2.67	Perf Half Y	-55.45%
Book/sh	4.36	P/B	0.72	EPS next Y	-20.90%	ROA	-21.70%	Target Price	19.00	Perf Year	-79.08%
Cash/sh	4.40	P/C	0.72	EPS next 5Y	-	ROE	-30.10%	52W Range	1.68 - 16.98	Perf YTD	-47.85%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-81.45%	Beta	-
Dividend %	-	Quick Ratio	14.70	Sales past 5Y	-	Gross Margin	-	52W Low	87.50%	ATR	0.34
Employees	202	Current Ratio	14.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	56.07	Volatility	13.47% 13.29%
Optionable	No	Debt/Eq	0.06	EPS Q/Q	27.90%	Profit Margin	-	Rel Volume	0.53	Prev Close	3.00
Shortable	Yes	LT Debt/Eq	0.03	Earnings	May 16 BMO	Payout	-	Avg Volume	216.40K	Price	3.15
Recom	1.50	SMA20	5.40%	SMA50	24.60%	SMA200	-53.24%	Volume	115,161	Change	5.00%

Apr-04-22

Initiated

BTIG Research

Buy

$18

Feb-03-21

Initiated

Citigroup

Buy

$35

Feb-02-21

Initiated

Wells Fargo

Overweight

$33

Feb-02-21

Initiated

Piper Sandler

Overweight

$40

Feb-02-21

Initiated

Jefferies

Buy

$30

May-26-22 05:01PM	Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting PR Newswire
May-19-22 08:30AM	Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences PR Newswire +7.96%
May-16-22 07:30AM	Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update GlobeNewswire
May-12-22 10:01AM	Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress PR Newswire +13.77%
May-04-22 08:30AM	Gracell Biotechnologies to Participate in Three Investor Conferences in May GlobeNewswire
May-02-22 08:00AM	Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022 GlobeNewswire +10.22%
Apr-28-22 10:30AM	Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting PR Newswire
Apr-22-22 05:00PM	Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021 GlobeNewswire
Apr-14-22 08:30AM	Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting PR Newswire -5.50%
Apr-08-22 04:00PM	Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL PR Newswire +5.99%
Mar-29-22 08:30AM	Gracell Biotechnologies to Participate in Three Investor Conferences in April GlobeNewswire
Mar-14-22 07:30AM	Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update GlobeNewswire -28.24%
Mar-10-22 04:30PM	Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference GlobeNewswire
Mar-08-22 04:30PM	Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 PR Newswire
Mar-02-22 08:00AM	Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022 GlobeNewswire
Mar-01-22 09:03AM	What Type Of Shareholders Own The Most Number of Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares? Simply Wall St.
Feb-22-22 07:30AM	Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform PR Newswire
Feb-17-22 08:30AM	Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma PR Newswire -5.32%
Feb-03-22 08:00AM	Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit GlobeNewswire
Jan-18-22 08:00AM	Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference GlobeNewswire
Jan-12-22 08:00AM	Gracell Biotechnologies Unveils Innovation Center in U.S. PR Newswire
Dec-25-21 02:38AM	Federated Hermes Prudent Bear Fund Buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, ... GuruFocus.com
Dec-16-21 08:00AM	Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index PR Newswire
Nov-23-21 09:00AM	Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan PR Newswire +22.10%
Nov-19-21 07:07AM	20 Stocks Moving in Friday's Pre-Market Session Benzinga
06:00AM	Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma PR Newswire
05:46AM	Gracell Biotech Gets Orphan Drug Nod For Myeloma Cell Therapy Investing.com
Nov-17-21 04:05PM	Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-15-21 07:30AM	Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-21 05:51AM	7 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global Insider Monkey
Nov-04-21 09:05AM	Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting PR Newswire
Nov-02-21 08:30AM	Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences GlobeNewswire
Oct-15-21 08:30AM	Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences GlobeNewswire
Aug-26-21 09:00AM	Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September GlobeNewswire -5.17%
Aug-17-21 07:00AM	Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update GlobeNewswire -11.57%
Aug-16-21 08:00AM	Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors PR Newswire
Aug-03-21 09:00AM	Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021 GlobeNewswire -6.76%
Jul-26-21 09:00AM	Gracell Biotechnologies to Participate in Fireside Chat at the BTIG Virtual Biotechnology Conference GlobeNewswire -7.05%
Jul-09-21 12:00PM	All You Need to Know About Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Rating Upgrade to Buy Zacks
Jun-02-21 08:30AM	Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 GlobeNewswire
May-26-21 09:00AM	Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma PR Newswire
May-25-21 04:01PM	Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June GlobeNewswire -15.80%
May-21-21 08:00AM	Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT GlobeNewswire +20.70%
May-19-21 05:15PM	Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 PR Newswire +11.77%
May-17-21 08:00AM	Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update GlobeNewswire +9.86%
May-10-21 04:01PM	Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer PR Newswire
Apr-30-21 05:32PM	Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May GlobeNewswire
Apr-23-21 06:00PM	Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020 GlobeNewswire
Apr-10-21 09:33AM	Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting PR Newswire
Apr-08-21 05:53AM	What Type Of Shareholders Make Up Gracell Biotechnologies Inc.'s (NASDAQ:GRCL) Share Registry? Simply Wall St. +7.27%
Apr-05-21 08:00AM	Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-21 08:45AM	Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S. PR Newswire
08:00AM	Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL PR Newswire
Mar-17-21 08:00AM	Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day GlobeNewswire
Mar-10-21 05:15AM	Gracell Biotechnologies Inc - ADR to Host Earnings Call ACCESSWIRE
Mar-09-21 04:01PM	Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update GlobeNewswire +7.26%
Jan-29-21 08:30PM	Tegna, Clear Channel Outdoor See Activist Action Barrons.com
Jan-19-21 06:30AM	Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL PR Newswire -6.25%
Jan-15-21 08:00AM	Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products PR Newswire
Jan-13-21 08:00AM	China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL PR Newswire
Jan-08-21 01:55AM	Gracell Biotechnologies Announces Pricing of Initial Public Offering PR Newswire

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience